Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Amortization of Deferred Charges (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Amortization of Deferred Charges for 7 consecutive years, with $783000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges rose 14.47% to $783000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 5.84% increase, with the full-year FY2025 number at $3.1 million, up 5.84% from a year prior.
  • Amortization of Deferred Charges was $783000.0 for Q4 2025 at Select Medical Holdings, roughly flat from $784000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $787000.0 in Q3 2024 to a low of $543000.0 in Q1 2021.
  • A 5-year average of $661750.0 and a median of $646500.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 32.74% in 2024; the steepest drop was 8.56% in 2024.
  • Select Medical Holdings' Amortization of Deferred Charges stood at $562000.0 in 2021, then rose by 2.49% to $576000.0 in 2022, then grew by 29.86% to $748000.0 in 2023, then decreased by 8.56% to $684000.0 in 2024, then rose by 14.47% to $783000.0 in 2025.
  • Per Business Quant, the three most recent readings for SEM's Amortization of Deferred Charges are $783000.0 (Q4 2025), $784000.0 (Q3 2025), and $786000.0 (Q2 2025).